Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Com-COV3 adolescent COVID-19 vaccine schedule study
ISRCTN12348322Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, single-blind trial of tozinameran, NVX-CoV2373 and meningococcal group B vaccine in coronavirus disease 2019 (COVID-19) (8 cohorts), sponsored by University of Oxford. Primary endpoint: Solicited systemic reactions. Started Sep 2021; status: completed.
02
Drugs
tozinameranNVX-CoV2373meningococcal group B vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN12348322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12348322.